A STUDY OF ATEZOLIZUMAB IN COMBINATION WITH EITHER OBINUTUZUMAB PLUS BENDAMUSTINE OR OBINUTUZUMAB PLUS (+) CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE, AND PREDNISONE (CHOP) IN PARTICIPANTS WITH FOLLICULAR LYMPHOMA (FL) OR RITUXIMAB + CHOP IN PARTICIPANTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL):